JP2019535262A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535262A5 JP2019535262A5 JP2019524412A JP2019524412A JP2019535262A5 JP 2019535262 A5 JP2019535262 A5 JP 2019535262A5 JP 2019524412 A JP2019524412 A JP 2019524412A JP 2019524412 A JP2019524412 A JP 2019524412A JP 2019535262 A5 JP2019535262 A5 JP 2019535262A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- car
- acid sequence
- sequence encoding
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 94
- 150000007523 nucleic acids Chemical group 0.000 claims description 88
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 73
- 210000004027 cell Anatomy 0.000 claims description 58
- 239000000427 antigen Substances 0.000 claims description 50
- 102000036639 antigens Human genes 0.000 claims description 50
- 108091007433 antigens Proteins 0.000 claims description 50
- 238000000034 method Methods 0.000 claims description 22
- 125000006850 spacer group Chemical group 0.000 claims description 20
- 239000013598 vector Substances 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
- 102000001493 Cyclophilins Human genes 0.000 claims description 14
- 108010068682 Cyclophilins Proteins 0.000 claims description 14
- 239000012190 activator Substances 0.000 claims description 14
- 229910052791 calcium Inorganic materials 0.000 claims description 14
- 239000011575 calcium Substances 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 210000000066 myeloid cell Anatomy 0.000 claims description 8
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 6
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 6
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 108020004705 Codon Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 206010052015 cytokine release syndrome Diseases 0.000 claims description 4
- 108010002082 endometriosis protein-1 Proteins 0.000 claims description 4
- 230000006801 homologous recombination Effects 0.000 claims description 4
- 238000002744 homologous recombination Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 3
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- SAZUGELZHZOXHB-UHFFFAOYSA-N acecarbromal Chemical compound CCC(Br)(CC)C(=O)NC(=O)NC(C)=O SAZUGELZHZOXHB-UHFFFAOYSA-N 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 230000004186 co-expression Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 230000031146 intracellular signal transduction Effects 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 210000003519 mature b lymphocyte Anatomy 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 230000002463 transducing effect Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 17
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 3
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201619097 | 2016-11-11 | ||
| GB1619097.7 | 2016-11-11 | ||
| PCT/GB2017/053386 WO2018087557A1 (en) | 2016-11-11 | 2017-11-10 | Chimeric antigen receptor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019535262A JP2019535262A (ja) | 2019-12-12 |
| JP2019535262A5 true JP2019535262A5 (enExample) | 2020-10-22 |
Family
ID=60627955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019524412A Pending JP2019535262A (ja) | 2016-11-11 | 2017-11-10 | キメラ抗原受容体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190352409A1 (enExample) |
| EP (1) | EP3538556A1 (enExample) |
| JP (1) | JP2019535262A (enExample) |
| CN (1) | CN110114371A (enExample) |
| AU (1) | AU2017357649A1 (enExample) |
| CA (1) | CA3042613A1 (enExample) |
| WO (1) | WO2018087557A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| AU2015221933B2 (en) | 2014-02-27 | 2019-09-12 | Autolus Limited | APRIL variants |
| CN111164203A (zh) * | 2017-08-02 | 2020-05-15 | 奥托路斯有限公司 | 表达嵌合抗原受体或工程化tcr并包含选择性表达的核苷酸序列的细胞 |
| US12492254B2 (en) | 2018-02-23 | 2025-12-09 | H. Lee Moffitt Cancer Center and Research Intitute. Inc. | CD83-binding chimeric antigen receptors |
| US20200108098A1 (en) * | 2018-02-23 | 2020-04-09 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Anti-cd83 chimeric antigen receptor expressing t regulatory cells |
| BR112021006182A2 (pt) * | 2018-10-01 | 2021-06-29 | Adicet Bio, Inc. | composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos |
| EP3934666A1 (en) * | 2019-03-08 | 2022-01-12 | Autolus Limited | Compositions and methods comprising engineered chimeric antigen receptor and modulator of car |
| US12023354B2 (en) | 2019-05-31 | 2024-07-02 | Case Western Reserve University | Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells |
| CN114206919B (zh) * | 2019-06-04 | 2025-07-15 | 综合医院公司 | 靶向taci的抗体和嵌合抗原受体 |
| GB2607716B (en) * | 2019-10-01 | 2024-10-30 | Univ Case Western Reserve | Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells |
| CN112779223B (zh) * | 2019-11-08 | 2024-06-11 | 浙江煦顼技术有限公司 | 偶联嵌合抗原受体细胞及其用途 |
| TW202146431A (zh) * | 2020-02-25 | 2021-12-16 | 英商圭爾醫療有限公司 | 用於經工程化細胞之嵌合受體 |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| CN118703444A (zh) * | 2021-01-22 | 2024-09-27 | 南京助天中科科技发展有限公司 | 一种嵌合抗原受体改造的nk细胞及其制备方法与应用 |
| US11359012B1 (en) | 2021-08-27 | 2022-06-14 | Nanjing Kaedi Biotherapeutics Ltd. | Specific chimeric antigen receptor cells targeting human CLDN18A2, preparation method and application thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9908807D0 (en) | 1999-04-16 | 1999-06-09 | Celltech Therapeutics Ltd | Synthetic signalling molecules |
| US20030012783A1 (en) * | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
| RU2005141512A (ru) * | 2003-05-31 | 2007-07-20 | Микромет Аг (De) | Фармацевтические композиции, включающие биспецифические анти-cd3, анти-cd19 конструкции антител для лечения расстройств, связанных с b-клетками |
| TWI679212B (zh) * | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US20130280220A1 (en) * | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| GB201317929D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| PL3071222T3 (pl) * | 2013-11-21 | 2021-04-19 | Ucl Business Ltd | Komórka |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| CN107849112B (zh) * | 2015-06-25 | 2022-04-01 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| MA42895A (fr) * | 2015-07-15 | 2018-05-23 | Juno Therapeutics Inc | Cellules modifiées pour thérapie cellulaire adoptive |
| CN105777911B (zh) * | 2016-04-12 | 2019-07-02 | 上海优卡迪生物医药科技有限公司 | 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 |
| EP4353750A3 (en) * | 2016-06-24 | 2024-07-24 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (cars), compositions and methods thereof |
-
2017
- 2017-11-10 CN CN201780080784.5A patent/CN110114371A/zh active Pending
- 2017-11-10 CA CA3042613A patent/CA3042613A1/en not_active Abandoned
- 2017-11-10 EP EP17811349.4A patent/EP3538556A1/en not_active Withdrawn
- 2017-11-10 WO PCT/GB2017/053386 patent/WO2018087557A1/en not_active Ceased
- 2017-11-10 AU AU2017357649A patent/AU2017357649A1/en not_active Withdrawn
- 2017-11-10 JP JP2019524412A patent/JP2019535262A/ja active Pending
- 2017-11-10 US US16/348,319 patent/US20190352409A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535262A5 (enExample) | ||
| JP2019150066A5 (enExample) | ||
| JP2022109953A5 (enExample) | ||
| JP2018523484A5 (enExample) | ||
| Robbins et al. | Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions | |
| JP7395249B2 (ja) | 細胞 | |
| JP7174522B2 (ja) | Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用 | |
| JP2021035395A5 (enExample) | ||
| US11180553B2 (en) | Chimeric antigen receptor | |
| CN112638947B (zh) | 用于治疗实体瘤的嵌合抗原受体细胞 | |
| CN110461335A (zh) | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 | |
| JP2021500852A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| JP2018532407A5 (enExample) | ||
| JP2017526361A5 (enExample) | ||
| CN113227379A (zh) | 多功能多靶向嵌合抗原受体（car）系统及其使用方法 | |
| JP2016538855A5 (enExample) | ||
| JP2018508215A5 (enExample) | ||
| JP2024023228A5 (enExample) | ||
| RU2016124280A (ru) | Клетка | |
| JP2023138960A (ja) | キメラ抗原受容体を発現する免疫細胞 | |
| RU2017121892A (ru) | Клетка | |
| CN115298208A (zh) | 免疫治疗用融合多肽 | |
| JP2015518479A5 (enExample) | ||
| CN109789164B (zh) | 具有gitr胞内结构域作为共刺激结构域的嵌合抗原受体 |